

REPUBLIC OF KOSOVA

KEKA Amir (amir.keka@rks-gov.net), KACURI Bujar (bujar.kacuri@rks-gov.net)
DOCI Njomza (njomza.doci@rks-gov.net) REXHEPI Teuta (teuta.m.rexhepi@rks-gov.net)
SYLA Mentor (mentor.syla@rks-gov.net), MURTEZI Fatbardha (fatbardha.murtezi@rks-gov.net)
Health Insurance Fund/Ministry of Health

PPRI Pharmaceutical Pricing and Reimbursement Information



Population – 1.773,971M, GDPPC: 4,500 €, Health expenditure: 5.6%

PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES

Pricing of medicines

price regulation is expected to be fully implemented during 2024 The Law on Medicinal Product Pricing has been approved in 2023. The competent authorities / decision making institutions for **pricing of medicines** is Ministry of Health.

This law shall apply to retail and wholesale distributors of medicinal products, the representative of the marketing authorization holder, the marketing authorization holder and public institutions.

Reference Countries: primary: Albania, Montenegro, North Macedonia, Croatia and the country of origin. secondary: Slovenia, Estonia, Bulgaria and the country of origin.

Calculate method: The price of the medicinal product is determined by calculating the average wholesale price of the two lowest prices of that product from the reference countries.

Type of comparator price – Wholesale price and CIP import prices Source of Pricing Information – Public official sources; Market Authorization Holders.

Price revisions frequency – regular price review annually or as required in cases of significant price changes.

Coverage Reimbursement

The Law on Health Insurance is towards finalization and expected to be fully implemented in coming years

The competent authorities /decision making institutions for **coverage /re-imbursement of** medicines are Ministry of Health and Health Insurance Fund.

The National Essential Medicine List (NEML) was updated during 2023. All the medicines from NEML are covered by public funds and there is no co-payment by patients (In-patient sector).

Upcoming: Out - Patient sector

Reimbursement policy will be determined by the government's decision on which drugs will be covered, the available budget and how much HIF covers.

The benefit will cover a very limited list of drugs that will be prescribed by the family medicine centre and will be provided free of charge in contracted private pharmacies.

The expansion of drugs will continue as revenues increase. There is no reimbursement for drugs that are not part of the reimbursement list.

HTA

Kosova doesn't have a fully established national HTA agency

Total expenditure in the health sector: 512M €

spending in the public sector: 293.4M € - Health Insurance: 21.99M €, OOP: 197.17M € OOP expenses account 38.5% of the total health expenses, of which 68.5% are only for medicines

the total expenditure on drugs amounts to 173.5 million ALL, 29% of which is covered by the state while 71% remains OOP.